Advertisement


Joaquim Bellmunt, MD, PhD, on Bladder Cancer: The Future of Immunotherapies

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Advertisement

Joaquim Bellmunt, MD, PhD, of Dana-Farber Cancer Institute, discusses refining treatment choices with new combinations and sequencing strategies.



Related Videos

Issues in Oncology
Immunotherapy

Aaron Goodman, MD, on Immune Checkpoint Blockade: Clinical Implications

Aaron Goodman, MD, of the University of California, San Diego School of Medicine, discusses an analysis of more than 100,000 patients with cancer for CD274 (PD-L1) amplification an...

Solid Tumors
Immunotherapy

Linda Mileshkin, MBBS, on Solid Tumors: Early Treatment Study Results

Linda Mileshkin, MBBS, of the Peter MacCallum Cancer Centre, discusses phase Ib trial findings on the anti–PD-1 monoclonal antibody BGB-A317 in combination with the PARP inhibitor ...

Leukemia
Immunotherapy

Kristen Fousek, PhD Candidate, on B-Cell ALL: CAR T-Cell Treatment

Kristen Fousek, PhD Candidate at Baylor College of Medicine, discusses her preclinical work on targeting CD19-negative relapsed B-cell acute lymphoblastic leukemia, using CAR T cel...

Immunotherapy

Ann W. Silk, MD, and Katy K. Tsai, MD: Meeting Highlights

Ann W. Silk, MD, of the Rutgers Cancer Institute of New Jersey, and Katy K. Tsai, MD, of the University of California, San Francisco, who are Co-Chairs of the Clin...

Hematologic Malignancies
Immunotherapy

Stephen M. Ansell, MD, PhD, on Hematologic Malignancies: Immunotherapy Update

Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses integrating immune checkpoint inhibitors, improving efficacy, and reducing toxicity when treating blood cancers.

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.